Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DarioHealth Corp.DRIO · Entity 7024 | Director · Chief Executive Officer | August 12, 2024 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DarioHealth Corp.
Report date August 12, 2024 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,432 |
Reported balance
After 2024-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-08-12 · Conversion · Acquired 579 · Balance 157,432 F1: Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. F2: The Reporting Person's 30 shares of Series B-2 Preferred Stock automatically converted into 11,574 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 579 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 157,432 shares of Common Stock immediately following the conversion. |
| Common StockSEC Table I · non-derivative | Direct | 454,432 |
Reported balance
After 2026-09-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-24 · Grant · Acquired 297,000 · Balance 454,432 F3: The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period. |
| Series B-2 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2024-08-04 | Direct | 0 |
Reported balance
After 2024-08-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-12 · Conversion · Disposed 30 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Dicilyon Consulting and Investment Ltd. | 1,894 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,894 |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.
F2: The Reporting Person's 30 shares of Series B-2 Preferred Stock automatically converted into 11,574 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 579 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 157,432 shares of Common Stock immediately following the conversion.
F3: The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2017 Filed Apr 17, 2017 16:26 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 10,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-020723 · v464390_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,700 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the second quarter of 2017 in the amount of $37,952.51. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 16:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantStock Option (right to buy) · Derivative | 143,164 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001144204-17-005358 · v457885_4.xml · derivative · entry 3 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,164 Underlying: Common Stock · 143,164 shares Expires 2023-01-30 F2 · derivative.exercise_date: The option vests in twelve equal quarterly installments commencing on January 30, 2017. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 16:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 11,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-005358 · v457885_4.xml · nonDerivative · entry 2 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,331 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the first quarter of 2017 in the amount of $36,443.60. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 16:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 227,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-005358 · v457885_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,950 Read SEC document |
| January 12, 2017 Filed Jan 13, 2017 16:42 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 11,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-002214 · v456901_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,334 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the fourth quarter of 2016 in the amount of $35,960.72. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.